November 2, 2020
Dr Reddy' s Laboratories Ltd on Thursday announced
its partnership with Biotechnology Industry Research
Assistance Council (BIRAC), Department of Biotechnology
(DBT), for advisory support on clinical trials of Sputnik
V vaccine in India.
According to a press release from the city-based drug maker,
the partnership will allow Dr Reddy' s to identify and use
some of BIRAC's clinical trial centres for the vaccine,
which are funded under the National Biopharma Mission (NBM),
implemented by Project Management Unit-NBM at BIRAC.
Further, the company will have access to Good Clinical
Laboratory Practice (GCLP) labs to conduct immunogenicity
assay testing of the vaccine. Immunogenecity refers to the
ability of an antigen to induce an immune response.
Chairman of Dr Reddys Laboratories, Satish Reddy said,
"We are pleased with the collaboration with BIRAC as an
advisory partner for clinical trials of the Sputnik V
vaccine in India. We look forward to working with them
to accelerate our efforts in bringing the vaccine to